Pharma Focus Asia

Specialised Therapeutics Announces Approval of MINJUVI® (tafasitamab)

Wednesday, June 28, 2023

Specialised Therapeutics announced the approval of a new therapy in Australia for the treatment of diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma in adults.

MINJUVI, also known as Monjuvi® (tafasitamab-cxix), has been approved for use in combination with lenalidomide. It is indicated for the treatment of adult patients with relapsed or refractory DLBCL (Diffuse Large B-Cell Lymphoma) not otherwise specified, including DLBCL arising from low-grade lymphoma, who are ineligible for autologous stem cell transplant (ASCT).

MINJUVI, an immunotherapy that targets CD19, has received approval not only in Australia but also in several other countries, including the United States (marketed as Monjuvi® with the generic name tafasitamab-cxix), Great Britain, Canada, Europe, and various other countries. This therapy functions by binding to the CD19 protein found on the surface of B-cell lymphoma cells, thereby stimulating an immune response against the lymphoma. 

Access to novel immune therapies, such as MINJUVI, is of significant importance for Australian patients, particularly those with relapsed DLBCL (Diffuse Large B-cell Lymphoma). 

Currently, CAR-T cell therapies, although effective, are only suitable for a limited proportion of DLBCL patients. Consequently, there is a crucial need for alternative treatment options. MINJUVI, represents a promising immune therapy for relapsed DLBCL.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024